← back to search

Michael Mante

University of California San Diego · US
Area of research
Neurology · Physiology
Research interest
Research interests include Parkinson's Disease Mechanisms and Treatments, Neurological Disorders and Treatments, Alzheimer's disease research and treatments, and Cholinesterase and Neurodegenerative Diseases.
h-index
48
citations
6,800
works
116
NIH funding
primary concept
email

Recent publications

Preclinical validation of a potent γ-secretase modulator for Alzheimer’s disease prevention
The Journal of Experimental Medicine 2021cited by 72position: middledoi
Effects of innate immune receptor stimulation on extracellular α-synuclein uptake and degradation by brain resident cells
Experimental & Molecular Medicine 2021cited by 40position: middledoi
Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease
Neurobiology of Disease 2019cited by 44position: middledoi
Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation
Molecular Neurodegeneration 2018cited by 155position: middledoi
LRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylation
Nature Communications 2018cited by 149position: middledoi
RETRACTED ARTICLE: Brain-derived exosomes from dementia with Lewy bodies propagate α-synuclein pathology
Acta Neuropathologica Communications 2017cited by 202position: middledoi
RETRACTED ARTICLE: Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy
Acta Neuropathologica Communications 2017cited by 92position: middledoi
RETRACTED: Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy
Neurobiology of Disease 2017cited by 85position: middledoi
Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy
Molecular Neurodegeneration 2015cited by 149position: middledoi
Appoptosin-Mediated Caspase Cleavage of Tau Contributes to Progressive Supranuclear Palsy Pathogenesis
Neuron 2015cited by 101position: middledoi
Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson’s disease
Journal of Neuroinflammation 2015cited by 66position: middledoi
Reducing C-Terminal-Truncated Alpha-Synuclein by Immunotherapy Attenuates Neurodegeneration and Propagation in Parkinson's Disease-Like Models
Journal of Neuroscience 2014cited by 317position: middledoi
RETRACTED: Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration <i>in vivo</i>
Brain 2014cited by 240position: middledoi
TOM40 Mediates Mitochondrial Dysfunction Induced by α-Synuclein Accumulation in Parkinson’s Disease
PLoS ONE 2013cited by 152position: middledoi
Antidepressants reduce neuroinflammatory responses and astroglial alpha‐synuclein accumulation in a transgenic mouse model of multiple system atrophy
Glia 2013cited by 80position: middledoi
S-Nitrosylation of parkin as a novel regulator of p53-mediated neuronal cell death in sporadic Parkinson’s disease
Molecular Neurodegeneration 2013cited by 79position: middledoi
Widespread micro<scp>RNA</scp>dysregulation in multiple system atrophy – disease‐related alteration in miR‐96
European Journal of Neuroscience 2013cited by 75position: middledoi
Age-dependent molecular alterations in the autophagy pathway in HIVE patients and in a gp120 tg mouse model: reversal with beclin-1 gene transfer
Journal of NeuroVirology 2013cited by 71position: middledoi
Role of α-Synuclein in Adult Neurogenesis and Neuronal Maturation in the Dentate Gyrus
Journal of Neuroscience 2012cited by 120position: middledoi
Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model
European Journal of Neuroscience 2012cited by 100position: middledoi
Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy
Experimental Neurology 2012cited by 86position: middledoi
Combined exposure to Maneb and Paraquat alters transcriptional regulation of neurogenesis-related genes in mice models of Parkinson’s disease
Molecular Neurodegeneration 2012cited by 83position: middledoi
Cerebrolysin modulates pronerve growth factor/nerve growth factor ratio and ameliorates the cholinergic deficit in a transgenic model of Alzheimer's disease
Journal of Neuroscience Research 2012cited by 64position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Edward Rockenstein · University of California San Diego22 papers (2012–2021)Eliezer Masliah · Institute on Aging22 papers (2012–2021)Anthony Adame · University of California, San Diego17 papers (2012–2021)Brian Spencer · University of Southern California10 papers (2012–2021)Kiren Ubhi · University of California San Diego7 papers (2012–2014)Christina Patrick · University of California San Diego7 papers (2012–2015)Robert A. Rissman · University of Southern California7 papers (2017–2021)Changyoun Kim · National Institutes of Health5 papers (2017–2021)Elvira Valera · University of California San Diego5 papers (2013–2017)Jazmin Florio · University of Southern California4 papers (2017–2021)Jürgen Winkler · Friedrich-Alexander-Universität Erlangen-Nürnberg4 papers (2012–2014)Beate Winner · Friedrich-Alexander-Universität Erlangen-Nürnberg3 papers (2012–2014) · 3 papers (2017–2021)Chandra Inglis · University of California San Diego3 papers (2012–2013)Jerel Adam Fields · University of California San Diego3 papers (2013–2021)Cassia Overk · University of California San Diego3 papers (2014–2017)Paula Desplats · University of California San Diego2 papers (2012–2013) · 2 papers (2018–2021)Deborah Masliah · University of California San Diego2 papers (2017–2018)Peter Seubert · Prothena (United States)2 papers (2014–2017)